Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial

International Journal of Obesity volume 25, pages 316–324 (2001)Cite this article

Abstract

OBJECTIVE: To examine in overweight humans the short-term safety and efficacy for weight loss of an herbal supplement containing Ma Huang, Guarana and other ingredients.

DESIGN: An 8 week randomized, double-blind placebo controlled study of a herbal dietary supplement (72 mg/day ephedrine alkaloids and 240 mg/day caffeine).

SUBJECTS: Overweight men and women (body mass index, ≥29 and ≤35 kg/m2).

MEASUREMENTS: The primary outcome variable was body weight change. Secondary variables included anthropometric, metabolic and cardiovascular changes.

RESULTS: Sixty-seven subjects were randomized to either placebo (n=32) or active Ma Huang/Guarana (n=35). Twenty-four subjects in each group completed the study. Active treatment produced significantly (P<0.006) greater loss of weight (X±s.d.,−4.0±3.4 kg) and fat (−2.1±3.0% fat) over the 8-week treatment period than did placebo (−0.8±2.4 kg and 0.2±2.3% fat). Active treatment also produced greater reductions in hip circumference and serum triglyceride levels. Eight of the 35 actively treated subjects (23%) and none of the 32 placebo-treated control subjects withdrew from the protocol because of potential treatment-related effects. Dry mouth, insomnia and headache were the adverse symptoms reported most frequently by the herbal vs placebo group at the final evaluation visit.

CONCLUSIONS: This herbal mixture of Ma Huang and Guarana effectively promoted short-term weight and fat loss. Safety with long-term use requires further investigation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Chen KK . A comparative study of synthetic and natural ephedrines J Pharmac Exp Ther 1929 34: 237–258.

    Google Scholar 

  2. Tyler VE . The honest herbal, 3rd edn Hayworth Press: Binghamton, Hayworth Press; New York 1993.

    Google Scholar 

  3. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL . Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991 JAMA 1994 272: 205–211.

    Article  CAS  Google Scholar 

  4. Han TS, Richmond P, Avenell A, Lean ME . Waist circumference reduction and cardiovascular benefits during weight loss in women Int J Obes Relat Metab Disord 1997 21: 127–134.

    Article  CAS  Google Scholar 

  5. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C . Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent. A randomized clinical trial JAMA 1998 280: 1596–1600.

    Article  CAS  Google Scholar 

  6. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M . Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults J Clin Pharmac 1997 37: 116–122.

    Article  CAS  Google Scholar 

  7. Astrup A, Breum L, Toubro S, Hein P, Quaade F . The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial Int J Obes Relat Metab Disord 1993 16: 269–277.

    Google Scholar 

  8. Betz JM, Gay ML, Mossoba MM, Adams S . Chiral gas chromatographic Determination of ephedrine-type alkaloids in dietary supplements containing Ma Huang J AOAC Int 1997 80: 303–315.

    CAS  PubMed  Google Scholar 

  9. Bukowiecki L, Jahjah L, Follea N . Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via beta-adrenoreceptors Int J Obes 1982 6: 343–350.

    CAS  PubMed  Google Scholar 

  10. Dulloo AG, Miller DS . The thermogenic properties of ephedrine/ methylxanthine mixtures: human studies Int J Obes 1986 10: 467–481.

    CAS  PubMed  Google Scholar 

  11. Dulloo AG, Miller DS . Reversal of obesity in the genetically obese fa/fa Zucker rat with an ephedrine/methylxanthines thermogenic mixture J Nutr 1987 117: 383–389.

    Article  CAS  Google Scholar 

  12. Dulloo AG, Miller S . The thermogenic properties of ephedrine/methylxanthine mixtures: animal studies Am J Clin Nutr 1986 43: 388–394.

    Article  CAS  Google Scholar 

  13. Toubro S, Astrup A, Breum L, Quaade F . Safety and efficacy of long-term treatment with ephedrine, caffeine, and ephedrine/ caffeine mixture Int J Obes Relat Metab Disord 1993 17: S69–S72.

    PubMed  Google Scholar 

  14. Malchow-Moller A, Larsen S, Hey H, Stokholm KH, Junl E, Quaade F . Ephedrine as an anorectic: the story of the ‘Elsinore pill’ Int J Obes 1981 5: 183–187.

    CAS  PubMed  Google Scholar 

  15. National Task Force on the Prevention and Treatment of Obesity . Long term pharmacotherapy in the management of obesity JAMA 1996 276: 1907–1915.

    Article  Google Scholar 

  16. Lohman TG . Advances in body composition assessment Human Kinetics: Champaigne, IL 1992.

    Google Scholar 

  17. Pi-Sunyer FX . Short-term medical benefits and adverse effects of weight loss Ann Intern Med 1993 119: 722–726.

    Article  CAS  Google Scholar 

  18. Dempster R, Aitkens S . A new air displacement method for determination of human body composition Med Sci Sports Exercise 1995 27: 1692–1697.

    Article  CAS  Google Scholar 

  19. Siri WE . Body composition from fluid spaces and density: analysis of methods In: Techniques for measuring body composition NAS: Washington, DC 1961. pp 223–248.

  20. Niklson IA, Reimitz PE, Sennef C . Factors that influence the outcome of placebo-controlled antidepressant clinical trials Psychopharmac Bull 1997 33: 41–51.

    CAS  Google Scholar 

  21. Astrup A, Toubro S, Cannon S, Hein P, Madsen J . Thermogenic, metabolic, and cardiovascular effects of a sympathomimietic agent, ephedrine Curr Ther Res 1990 48: 1087–1100.

    Google Scholar 

  22. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L . Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity Int J Obes Relat Metab Disord 1993 17: S73–S78.

    PubMed  Google Scholar 

  23. Astrup A, Toubro S, Cannon S, Hein P, Madsen J . Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double blind placebo-controlled study Metabolism 1991 40: 323–329.

    Article  CAS  Google Scholar 

  24. Ramsey JJ, Colman RJ, Swick AG, Kemnitz JW . Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine Am J Clin Nutr 1998 68: 42–51.

    Article  CAS  Google Scholar 

  25. Dulloo AG . Ephedrine, xanthines and prostaglandin-inhibitors; actions and interactions in the stimulation of thermogenesis Int J Obes Relat Metab Disord 1993 17: S35–S40.

    CAS  PubMed  Google Scholar 

  26. Pasquali R, Casimirri F . Clinical aspects of ephedrine in the treatment of obesity Int J Obes Relat Metab Disord 1993 17: S65–S68.

    PubMed  Google Scholar 

  27. Breum L, Pedersen JK, Ahlstrom F, Frimodt-Moller J . Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice Int J Obes Relat Metab Disord 1994 18: 99–103.

    CAS  PubMed  Google Scholar 

  28. Svendsen TL, Ingerslev J, Mork A . [Is Letigen contraindicated in hypertension? A double-blind, placebo controlled multipractice study of letigen administered to normotensive and adequately treated patients with hypersensitivity] Ugeskr Laeger 1998 160: 4073–4075.

    CAS  PubMed  Google Scholar 

  29. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR . Pharmaceutical cost savings of treating obesity with weight loss medications Obes Res 1999 716: 523–530.

    Article  Google Scholar 

  30. Dulloo AG, Stock MJ . Editorial Int J Obes Relat Metab Disord 1993 17: S1–S2.

    PubMed  Google Scholar 

  31. Miura T, Tatara M, Nakamura K, Suzuki I . Effect of Guarana on exercise in normal and ephedrine-induced glycogenolytic mice Biol Pharm Bull 1998 21: 646–648.

    Article  CAS  Google Scholar 

  32. Klepser TB, Klepser ME . Unsafe and potentially safe herbal therapies Am J Health Syst Pharm 1999 56: 138.

    Article  Google Scholar 

  33. Anonymous . Adverse events associated with ephedrine-containing products—Texas, December 1993–September 1995 Morb Mortal Wkly Rep 1996 45: 689–693.

    Google Scholar 

  34. 62 Federal Register 30678

  35. GAO/HEHS/GGD-99-90 . Dietary supplements: uncertainities in analyses underlying FDA's proposed rule on ephedrine alkaloids

  36. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB . Sibutramine produces dose-related weight loss Obes Res 1999 7 189–198.

    Article  CAS  Google Scholar 

  37. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P . Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study Int J Obes Relat Metab Disord 1998 22: 32–38.

    Article  CAS  Google Scholar 

  38. Weintraub J, Rubio A, Golik A, Byrne L, Scheinbaum ML . Sibutramine in weight control: a dose-ranging, efficacy study Clin Pharmac Ther 1991 50: 330–337.

    Article  CAS  Google Scholar 

  39. Hannotin C, Thomas F, Jones SP, Leutenegger E, Drouin P . A comparison of sibutramine and dexfenfluramine in the treatment of obesity Obes Res 1998 6: 285–291.

    Article  Google Scholar 

  40. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A . Thermogenic effects of sibutramine in humans Am J Clin Nutr 1998 68: 1180–1186.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Research support was provided by: Science Toxicology and Technology Consulting, San Francisco, CA; Metabolife Inc., San Diego, CA; and National Institutes of Health grant P30DK 26687. The authors acknowledge the following individuals for their assistance in carrying out this investigation: Stanley Heshka PhD, for the randomization procedure; Peter Hommel PhD for statistical advice; and the medical staff for physical evaluations—Abderrahmane Saddouk MD, Adbelhakim Dinar MD, Grace Marin and Renee Gabrielle.

Author information

Authors and Affiliations

  1. St Luke's-Roosevelt Hospital Center and Department of Medicine, Obesity Research Center, Columbia University College of Physicians and Surgeons, New York, USA

    CN Boozer, JA Nasser, SB Heymsfield, V Wang, G Chen & JL Solomon

Authors
  1. CN Boozer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JA Nasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. SB Heymsfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JL Solomon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to CN Boozer.

Appendix

Appendix

Reported composition of Metabolife-356 (Metabolife Inc., San Diego, CA): Vitamin E, 6 IU; magnesium protein chelate, 75 mg; zinc chelate, 5 mg; chromium picolinate, 75 µg; proprietary blend, 728 mg; Guarana, 40 mg; Ma Huang, 12 mg; bee pollen; ginseng (root); ginger (root); damiana (leaf); sarsaparilla (root); goldenseal (aerial part); nettles (leaf); bovine complex; gotu kola; lecithin; spirulina algae; royal jelly; and other ingredients (binders, etc), methacel, silica, croscarmellose sodium and magnesium stearate.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boozer, C., Nasser, J., Heymsfield, S. et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes 25, 316–324 (2001). https://doi.org/10.1038/sj.ijo.0801539

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0801539

Keywords

This article is cited by

Search

Advanced search

Quick links